Search Results - "Lieu, C. H."

Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer by Chen, Z-Y, Raghav, K, Lieu, C H, Jiang, Z-Q, Eng, C, Vauthey, J-N, Chang, G J, Qiao, W, Morris, J, Hong, D, Hoff, P, Tran, H, Menter, D G, Heymach, J, Overman, M, Kopetz, S

“…Background: High circulating neutrophil-lymphocyte ratio (NLR) appears to be prognostic in metastatic colorectal cancer (mCRC). We investigated the…”
Get full text

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts by Capasso, A, Lang, J, Pitts, T M, Jordan, K R, Lieu, C H, Davis, S L, Diamond, J R, Kopetz, S, Barbee, J, Peterson, J, Freed, B M, Yacob, B W, Bagby, S M, Messersmith, W A, Slansky, J E, Pelanda, R, Eckhardt, S G

“…The success of agents that reverse T-cell inhibitory signals, such as anti-PD-1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However,…”
Get full text

Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix by Lieu, C.H., Lambert, L.A., Wolff, R.A., Eng, C., Zhang, N., Wen, S., Rafeeq, S., Taggart, M., Fournier, K., Royal, R., Mansfield, P., Overman, M.J.

“…Poorly differentiated and signet ring cell adenocarcinomas of the appendix represent a subset with aggressive tumor biology and poor outcomes with few studies…”
Get full text

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial by Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T.

“…The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and…”
Get full text

Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders by Lieu, C.-H., Wu, H.-S., Hon, Y.-C., Tsai, W.-H., Yang, C.-F., Wang, C.-C., Lin, Y.-C., Shih, C.-H., Hsu, H.-C.

“…Background:  The Janus kinase‐2 (JAK‐2) V617F mutation has been recently reported in patients with myeloproliferative disorders (MPD), which is believed to…”
Get full text

Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study by Oba, A, Wu, Y H A, Lieu, C H, Meguid, C, Colborn, K L, Beaty, L, Al-Musawi, M H, Davis, S L, Leal, A D, Purcell, T, King, G, Wooten, E S, Fujiwara, Y, Goodman, K A, Schefter, T, Karam, S D, Gleisner, A L, Ahrendt, S, Leong, S, Messersmith, W A, Schulick, R D, Del Chiaro, M

“…Use of neoadjuvant therapy for elderly patients with pancreatic cancer has been debatable. With FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan,…”
Get full text

dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state by O'Bryant, C. L, Lieu, C. H, Leong, S, Boinpally, R, Basche, M, Gore, L, Leonardi, K, Schultz, M. K, Hariharan, S, Chow, L, Diab, S, Gibbs, A, Eckhardt, S. G

“…Purpose To evaluate the safety, pharmacokinetics and determine the recommended dose of the selective apoptotic antineoplastic drug, OSI-461 administered on a…”
Get full text

Dual cytotoxic mechanisms of submicromolar taxol on human leukemia HL-60 cells by Lieu, Chien-Hui, Chang, Yen-Ni, Lai, Yiu-Kay

“…Taxol-induced mitotic block and apoptosis were investigated using taxol-sensitive human leukemia HL-60 cells at submicromolar concentrations of the drug. Cells…”
Get full text

Evaluation of anti-Wnt/β-catenin signaling agents by pGL4-TOP transfected stable cells with a luciferase reporter system by Chuang, K A, Lieu, C H, Tsai, W J, Wu, M H, Chen, Y C, Liao, J F, Wang, C C, Kuo, Y C

“…Refractory and relapsed leukemia is a major problem during cancer therapy, which is due to the aberrant activation of Wnt/β-catenin signaling pathway…”
Get full text

Implementation of CLAIRE, traffic estimation and prediction system, and adaptive traffic control in the US by Ghaman, R.S, Lieu, H.C, Scemama, G

“…Over the years, the Federal Highway Administration Research, Development and Technology (FHWA RD&T) has been developing hardware and software tools that will…”
Get full text

From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development by LIEU, Christopher H, TAN, Aik-Choon, LEONG, Stephen, DIAMOND, Jennifer R, GAIL ECKHARDT, S

“…The development of targeted agents in oncology has rapidly expanded over the past 2 decades and has led to clinically significant improvements in the treatment…”
Get full text

Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in the Rapid Induction of the 78-kDa Glucose-regulated Protein in 9L Rat Brain Tumor Cells by Chen, Kuang-Den, Chen, Liuh-Yow, Huang, Huei-Luen, Lieu, Chien-Hui, Chang, Yen-Ni, Chang, Margaret Dah-Tysr, Lai, Yiu-Kay

“…We have previously shown that treatment with okadaic acid (OA) followed by heat shock (HS) (termed OA → HS treatment) leads to rapid transactivation of the…”
Get full text

Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells by LIEU, C.-H, LIU, C.-C, YU, T.-H, CHEN, K.-D, CHANG, Y.-N, LAI, Y.-K

“…The induction of apoptosis by Taxol was investigated in human leukemic U937 cells. Treatment of U937 cells with 20 nM Taxol for 24 h induced apoptosis in…”
Get full text

The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer by Lieu, C. H., Tran, H. T., Jiang, Z., Mao, M., Overman, M. J., Eng, C., Morris, J., Ellis, L. M., Heymach, J., Kopetz, S.

“…Abstract only…”
Get full text

Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer by Lieu, C. H., Tran, H. T., Fiorentino, S., Jiang, Z., Mao, M., Overman, M. J., Eng, C., Ellis, L. M., Heymach, J., Kopetz, S.

“…Abstract only 401 Background: CAFs were previously shown to be modulated in patients (pts) with metastatic colorectal cancer (mCRC) after…”
Get full text

Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers by Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D., Sieber, O., Desai, J.

“…Abstract only…”
Get full text

Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer by Lieu, C. H., Wolff, R. A., Eng, C., Overman, M. J., Henry, L., Coulson, R., Garrett, C. R., Abbruzzese, J. L., Gallick, G. E., Kopetz, S.

“…Abstract only…”
Get full text

Design and synthesis of new taxol-containing aminophosphates as protaxols by Jih Ru Hwu, Hakimelahi, Gholam H., Sambaiah, Thota, Patel, Himatkumar V., Shwu-Chen Tsay, Yiu-Kay Lai, Chien-Hui Lieu

“…Taxol-containing aminophosphates 5–7 were synthesized as protaxols by a “one-flask” method; the intrinsic zwitterionic character increases their solubility to…”
Get full text

Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix by Lieu, C H, Lambert, L A, Wolff, R A, Eng, C, Zhang, N, Wen, S, Rafeeq, S, Taggart, M, Fournier, K, Royal, R, Mansfield, P, Overman, M J

“…Poorly differentiated and signet ring cell adenocarcinomas of the appendix represent a subset with aggressive tumor biology and poor outcomes with few studies…”
Get full text

Cell cycle specific induction of apoptosis and necrosis by paclitaxel in the leukemic U937 cells by Liao, Pei-Chin, Lieu, Chien-Hui

“…Induction of cell apoptosis and necrosis by paclitaxel was investigated in human leukemic U937 cells. To explore whether paclitaxel induces both apoptosis and…”
Get full text